The role of high-potency benzodiazepines in the treatment of panic disorder

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 7, Issue 1, 2005, Pages 5-11

  Susman, Jeffrey ^a   Klee, Brian ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CLONAZEPAM; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT;

AREA UNDER THE CURVE; ATAXIA; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DELAYED RELEASE FORMULATION; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; MEMORY DISORDER; MENTAL DISEASE; NEUROBIOLOGY; PANIC; PATIENT EDUCATION; PRACTICE GUIDELINE; PSYCHOTHERAPY; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TRANQUILIZING ACTIVITY; WITHDRAWAL SYNDROME;

EID: 28244452085     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/PCC.v07n0101     Document Type: Review

References (48)

1. Eaton WW, Kessler RC, Wittchen HU, et al. Panic and panic disorder in the United States. Am J Psychiatry 1994;151:413-420
2. Roy-Byrne PP, Stang P, Wittchen HU, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey: association with symptoms, impairment, course and help-seeking. Br J Psychiatry 2000;176: 229-235
3. Birchall H, Brandon S, Taub N. Panic in a general practice population: prevalence, psychiatric comorbidity and associated disability. Soc Psychiatry Psychiatr Epidemiol 2000;35:235-241
4. Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505
5. Horesh N, Amir M, Kedem P, et al. Life events in childhood, adolescence and adulthood and the relationship to panic disorder. Acta Psychiatr Scand 1997;96:373-378
6. Nutt D, Feeney A, Argyropoulos S. Anxiety Disorders Comorbid With Depression: Panic Disorder and Agoraphobia. London, UK: Martin Dunitz Ltd; 2002
7. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001;179:390-396
8. Lydiard RB. The role of GABA in anxiety disorder. J Clin Psychiatry 2003;64(suppl 3):21-27
9. Malizia AL, Cunningham VJ, Bell CJ, et al. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998;55:715-720
10. 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry 2001;58:556-561
11. A receptor subtypes. Nature 1999; 401:796-800
12. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Panic Disorder. Am J Psychiatry 1998;155(suppl 5): 1-34
13. Saeed SA, Bruce TJ. Panic disorder: effective treatment options. Am Fam Physician 1998;57:2405-2412
14. Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998;18(suppl 2):12S-18S
15. Culpepper L. Identifying and treating panic disorder in primary care. J Clin Psychiatry 2004;65(suppl 5):19-23
16. Doyle A, Pollack MH. Long-term management of panic disorder. J Clin Psychiatry 2004;65(suppl 5):24-28
17. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004;65(suppl 5):7-12
18. IMS Health. National Prescription Audit. NAT. Available at http:// www.imshealth.com. Accessed August 2003
19. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 2003;160:1432-1438
20. Otto MW, Smits JA, Reese HE. Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry 2004;65(suppl 5):34-41
21. Uhlenhuth EH, DeWit H, Baiter MB, et al. Risks and benefits of long-term benzodiazepine use. J Clin Psychopharmacol 1988;8:161-167
22. Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J Clin Psychiatry 2002;63(suppl 14):27-33
23. Schweizer E, Patterson W, Rickeis K, et al. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993;150:1210-1215
24. Stahl SM. Alprazolam XR: dosage considerations. Psychiatr Ann 1993;23(suppl 10):27-31
25. Wright CE. Clinical pharmacokinetics of alprazolam extended release: a summary. Curr Ther Res 1995;56:947-956
26. Xanax XR [package insert]. New York, NY: USPI, Pfizer Inc; 2003
27. Klonopin Tablets and Wafers [package insert]. Basel, Switzerland: USPI, Roche; 2001
28. Moroz G. High-potency benzodiazepines: recent clinical results. J Clin Psychiatry 2004;65(suppl 5):13-18
29. Chouinard G, Annable L, Fontaine R, et al. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology (Berl) 1982;77:229-233
30. Ballenger JC, Burrows GD, DuPont RL Jr, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, 1: efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-422
31. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989;9:22-27
32. Pecknold J, Luthe L, Munjack D, et al. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 1994;14:314-321
33. Alexander PR. Alprazolam-XR in the treatment of panic disorder: results of a multicenter study. Psychiatr Ann 1993;23(suppl 10):14-19
34. Mumford GK, Evans SM, Fleishaker JC, et al. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 1995;57:356-365
35. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol 1997;17:390-400
36. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76
37. Rickels K, Rynn M. Pharmacology of generalized anxiety disorder. J Clin Psychiatry 2002;63(suppl 14):9-16
38. Roy-Byrne P, Russo J, Pollack M, et al. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med 2003;33:511-518
39. Rickels K, DeMartinis N, Rynn M, et al. Pharmacologic strategies for discontinuing benzodiazepines treatment. J Clin Psychopharmacol 1999; 19(suppl 2):12S-16S
40. Pecknold J, Alexander PE, Munjack D. Alprazolam XR in the management of anxiety: discontinuations. Psychiatr Ann 1993;23(suppl):38-44
41. Figueira ML. Alprazolam extended release in the management of anxiety. Curr Ther Res 1995;56:957-965
42. Klein E, Colin V, Stolk J, et al. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry 1994;151:1760-1766
43. Klein E. Discontinuation of benzodiazepines in patients with anxiety disorder: a focus on alprazolam and alprazolam extended release. Curr Ther Res 1995;56:969-974
44. Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681-686
45. Pollack MH, Simon NM, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003;17:276-282
46. Sheehan DV. The management of panic disorder. J Clin Psychiatry 2002;63(suppl 14):17-21
47. Rickels K, Schweizer E. Panic disorder: long-term psychotherapy and discontinuation. J Clin Psychopharmacology 1998;59(suppl 8):30-36
48. Williams DD, McBride A. Benzodiazepines: time for reassessment. Br J Psychiatry 1998;173:361-362